Key result
Immunization with yeast-produced EV71-VLPs at 1-5 µg/dose with 225 µg adjuvant induced robust neutralizing antibody responses and provided 100% protection against lethal EV71 challenge in neonatal mice.
Why the study?
An efficient recombinant methodology was needed to produce an effective, safer, and easily scalable virus-like particle (VLP)-based EV71 vaccine against hand, foot and mouth disease.
Absolute Event Rate: 100% vs 0%
Yeast-produced EV71-VLPs antigen induces robust neutralizing antibodies and protects against lethal challenge in mouse models, representing a promising candidate for an HFMD vaccine.
Supports progression of EV71-VLP vaccine to clinical testing; leaves open human immunogenicity and efficacy.
Enterovirus 71 (EV71) is one of the major causative agents for hand, foot and mouth disease (HFMD) in children. Although there are three inactivated virus-based HFMD vaccines licensed in China, alternative approaches have been taken to produce an effective and safer vaccine that is easier to manufacture in large scale. Among these, a virus-like particles (VLPs) based EV71 vaccine is under active development. For this purpose, an efficient methodology for the production of EV71-VLPs by recombinant technology is needed. We here report the construction and expression of the P1 and 3C genes of EV71 in Pichia pastoris for producing VLP-based EV71 vaccine antigen with a high yield and simple manufacturing process. Based on codon-optimized P1 and 3C genes, EV71-VLPs were efficiently expressed in Pichia pastoris system, and the expression level reached 270 mg/L. Biochemical and biophysical analyses showed that the produced EV71-VLPs consisted of processed VP0, VP1, and VP3 present as ~35nm spherical particles. The immune response as a function of EV71-VLPs and adjuvant dose ratio was investigated for vaccine development. Immunization with EV71-VLPs of 1–5 µg/dose and adjuvant of 225 µg/dose induced robust neutralizing antibody responses in mice and provided effective protection against lethal challenge in both maternally transferred antibody and passive transfer protection mouse models. Therefore, the yeast produced EV71-VLPs antigen is a promising candidate for the development of a vaccine against HFMD.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2019) studied Enterovirus 71 (EV71) infection. EV71-VLPs vaccine vs. Inactivated EV71 vaccine or adjuvant alone was evaluated on Survival rate after lethal EV71 challenge in neonatal mice. Immunization with yeast-produced EV71-VLPs at 1-5 µg/dose with 225 µg adjuvant induced robust neutralizing antibody responses and provided 100% protection against lethal EV71 challenge in neonatal mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: